# Splicebio, S.L.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/splicebio-s-l

- Industry: Biotechnology
- Headquarters: Barcelona, Spain
- Website: www.splice.bio
- Total disclosed funding: $193M
- Latest round: Series B (Jun 1, 2025)
- Investors on record: 10

## About

Splicebio, S.L. develops innovative gene therapy solutions utilizing proprietary protein splicing technology, aiming to enhance the treatment of rare genetic diseases through precise and efficient genetic medicine delivery. Founded in 2012 in Barcelona, Spain, SpliceBio SL specializes in gene therapy solutions and has undergone strategic developments to focus on advancing treatments for rare diseases. The company was established by Sílvia Frutos, who has a strong background in biotechnology. In June 2025, SpliceBio SL raised EUR 118 million in series B funding co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from other new investor Roche Venture Fund. Returning investors Asabys Partners, Novartis Venture Fund, Gilde Healthcare Partners, Ysios Capital Partners, UCB Ventures, New Enterprise Associates, and other unspecified investors also participated in the round. SpliceBio, S.L. specializes in innovative gene therapy solutions through its proprietary protein splicing technology. This core offering focuses on the precise and efficient delivery of genetic medicines, targeting therapeutic development for rare diseases. The company’s products are designed to enhance protein engineering, addressing critical medical conditions that lack effective treatments. SpliceBio’s technologies leverage the pioneering research of its founders, particularly in intein-mediated protein splicing, to create novel therapeutic modalities. Their client base primarily consists of biotechnology and pharmaceutical companies looking to advance their therapeutic pipelines, with a particular emphasis on markets in North America and Europe. The revenue model is structured around collaborations with biotech firms and pharmaceutical companies, integrating its proprietary gene therapy technologies through various agreements, including licensing deals and research funding. This model supports SpliceBio's flagship products while enabling continuous growth and investment in research and development. The company will use the series B funding for the advancement of its phase I/II trials of its lead compound SB-007.

## Funding rounds

- Series B, Jun 1, 2025, $134M — New Enterprise Associates, Novartis Venture Fund, EQT Life Sciences, Gilde Healthcare, Ysios Capital Partners, Roche Venture Fund, Sanofi Ventures, Asabys Partners, UCB Ventures
- Series A, Feb 15, 2022, $57M — New Enterprise Associates, Novartis Venture Fund, Gilde Healthcare, Ysios Capital Partners, Asabys Partners, UCB Ventures
- Series A, Feb 28, 2018, $2.1M — Caixa Capital Risc

## Investors

- Caixa Capital Risc — Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A, Series B
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series A, Series B
- Asabys Partners (https://capitalatlas.ai/funds/asabys-partners) — Series A, Series B
- UCB Ventures (https://capitalatlas.ai/funds/ucb-ventures) — Series A, Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B